A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: favourite (50), first choice (404)

InP Cyclophosphamide Doxorubicin Etoposide Vincristine VCDEVer1

Description
Chemotherapy Protocol SARCOMA DOXORUBICIN-CYCLOPHOSPHAMIDE-ETOPOSIDE-VINCRISTINE (VCDE) Inpatient Regimen Regimen Sarcoma-InP- Cyclophospha
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InPCyclophosphamideDoxorubicinEtoposideVincristineVCDEVer1.pdf

Cytarabine_2000_FludarabineIdarubicin_FLA-Ida

Description
Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CYTARABINE (2000)-FLUDARABINE-IDARUBICIN (FLA-IDA) In-Patient Regimen Regimen • Acute Myeloid Leukaemia – InP-Cyta
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Cytarabine-2000-FludarabineIdarubicin-FLA-Ida.pdf

Papers Trust Board - 15 July 2025

Description
Agenda Trust Board – Open Session Date 15/07/2025 Time 9:00 - 13:00 Location Conference Room, Heartbeat Education Centre Chair
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-15-July-2025.pdf

Spinal enhanced recovery programme - patient information

Description
This factsheet explains what the spinal enhanced recovery programme is and what to expect in the days before and after your
Url
/Media/UHS-website-2019/Patientinformation/Brain-and-spine/Spinal-enhanced-recovery-programme-2966-PIL.pdf

Epcoritamab -Cycle 2 (Onwards)

Description
Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onwards - (28
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

Epcoritamab -Cycle 1 (Priming)

Description
Chemotherapy Protocol LYMPHOMA EPCORITAMAB -Cycle 1 - (28 Day -Priming) Regimen • Lymphoma-Epcoritamab – Cycle 1- (28 day -Pri
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-1-Priming-Ver1.pdf

End of life care strategy - patient information

Description
A strategy for end of life care.
Url
/Media/UHS-website-2019/Patientinformation/Bereavement-and-end-of-life/End-of-life-care-strategy-3687-PIL.pdf

Atezolizumab (1875mg 21-days) SC

Description
Chemotherapy Protocol UROTHELIAL CANCER Atezolizumab SC (1875mg – 21 days) Regimen • Urothelial cancer – Atezolizumab monotherapy (1st or 2nd
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab-SC-1875mg-21-days.pdf

NIHR_RTB_PIS-ICF_v5.0_04APR2024_Localised

Description
PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 5.0 04th April 2024 *If you require this information to
Url
/Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-PIS-ICF-v5.0-04APR2024-Localised.pdf

NIHR_RTB_PIS-ICF_v5.0_04APR2024_Localised.cleaned

Description
PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 5.0 04th April 2024 *If you require this information to
Url
/Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-PIS-ICF-v5.0-04APR2024-Localised.cleaned.pdf
51 to 60 of 97
Previous … 4 5 6 7 8 … Next